Romiplostim 500 µg [clinicaltrials_resource:NCT00413283/group/E3]
Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Hyperlipidaemia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/100/count/399]Hypoglycaemia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/101/count/403]Hypokalaemia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/102/count/407]Hypomagnesaemia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/103/count/411]Hyponatraemia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/104/count/415]Arthralgia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/105/count/419]Back pain for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/106/count/423]Bone pain for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/107/count/427]Joint swelling for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/108/count/431]Muscle fatigue for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/109/count/435]Muscular weakness for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/110/count/439]Musculoskeletal chest pain for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/111/count/443]Musculoskeletal pain for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/112/count/447]Myalgia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/113/count/451]Pain in extremity for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/114/count/455]Cancer pain for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/115/count/459]Amnesia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/116/count/463]Burning sensation for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/117/count/467]Dizziness for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/118/count/471]Headache for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/119/count/475]Hypoaesthesia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/120/count/479]Neuropathy peripheral for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/121/count/483]Paraesthesia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/122/count/487]Syncope for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/123/count/491]Tremor for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/124/count/495]Confusional state for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/125/count/499]Depression for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/126/count/503]Insomnia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/127/count/507]Restlessness for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/128/count/511]Haematuria for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/129/count/515]Nocturia for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/130/count/519]Renal failure for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/131/count/523]Renal pain for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/132/count/527]Urinary incontinence for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/133/count/531]Chronic obstructive pulmonary disease for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/134/count/535]Cough for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/135/count/539]Dyspnoea for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/136/count/543]Epistaxis for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/137/count/547]Haemoptysis for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/138/count/551]Pleural effusion for NCT00413283 for E3 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/139/count/555]
group [clinicaltrials_vocabulary:group]
Romiplostim 500 µg [clinicaltrials_resource:NCT00413283/group/E3]
Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Bio2RDF identifier
NCT00413283/group/E3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00413283/group/E3
group id [clinicaltrials_vocabulary:group-id]
description
Participants received romiplos ...... andard institutional practice.
@en
identifier
clinicaltrials_resource:NCT00413283/group/E3
title
Romiplostim 500 µg
@en
type
label
Romiplostim 500 µg [clinicaltrials_resource:NCT00413283/group/E3]
@en